Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2004-03-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM034243OPMID 15084115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs).

  2003cited by this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

  2003cited by this paper
• Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.

  2003cited by this paper
• Advances in the science of estrogen receptor modulation.

  2003cited by this paper
• Dehydrative reduction: a highly diastereoselective synthesis of syn-bisaryl(or heteroaryl) dihydrobenzoxathiins and benzodioxane.

  2003cited by this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.

  2003cited by this paper
• Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.

  2002cited by this paper
• EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.

  2001cited by this paper
• Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens.

  2001cited by this paper
• Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

  1999cited by this paper
• Emerging therapies for the prevention or treatment of postmenopausal osteoporosis.

  1999cited by this paper
• Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.

  1998cited by this paper
• Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.

  1998cited by this paper
• Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.

  1997cited by this paper
• Molecular determinants of tissue selectivity in estrogen receptor modulators.

  1997cited by this paper
• Cloning of a novel receptor expressed in rat prostate and ovary.

  1996cited by this paper
• ER beta: identification and characterization of a novel human estrogen receptor.

  1996cited by this paper
• Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

  1993cited by this paper

• Optimization of harvest time for medicinal use of Acorus tatarinowii Schott: A comprehensive analytical approach using HS-SPME-GC-MS, network pharmacology, and molecular simulation techniques

  2025cites this paper
• Unveiling the Bioactive Efficacy of Cupressus sempervirens ‘Stricta’ Essential Oil: Composition, In Vitro Activities, and In Silico Analyses

  2024cites this paper
• Anti-Cancer Activity, DFT and molecular docking study of new BisThiazolidine amide

  2024cites this paper
• Repurposing Phytochemicals against Breast Cancer (MCF-7) using Classical Structure-Based Drug Design.

  2024cites this paper
• Synthesis of 2,3-dihydro-1,4-benzoxathiine derivatives

  2022cites this paper
• Synthesis of spiro[imidazole-4,3'-thiochroman]ones from [2-(benzylsulfanyl)benzylidene]imidazolones

  2022cites this paper
• Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs

  2022influential citation
• Human Estrogen Receptor Alpha Antagonists, Part 3: 3-D Pharmacophore and 3-D QSAR Guided Brefeldin A Hit-to-Lead Optimization toward New Breast Cancer Suppressants

  2022influential citation
• ERpred: a web server for the prediction of subtype-specific estrogen receptor antagonists

  2021cites this paper
• Human Estrogen Receptor α Antagonists. Part 1: 3-D QSAR-Driven Rational Design of Innovative Coumarin-Related Antiestrogens as Breast Cancer Suppressants through Structure-Based and Ligand-Based Studies

  2021cites this paper
• Ligand Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies of Asymmetrical Hexahydro-2H-Indazole Analogs of Curcumin (AIACs) to Discover Novel Estrogen Receptors Alpha (ERα) Inhibitor

  2020cites this paper
• Directed synthesis of fluorine containing 2,3-dihydrobenzo[b][1,4]oxathiine derivatives from polyfluoroarenes

  2020cites this paper
• Optimisation of estrogen receptor subtype-selectivity of a 4-Aryl-4H-chromene scaffold previously identified by virtual screening.

  2019cites this paper
• Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer.

  2019cites this paper
• Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy

  2019cites this paper
• Continuous-Flow Electrosynthesis of Benzofused S-Heterocycles by Dehydrogenative C-S Cross-Coupling.

  2019cites this paper
• Graph Convolutional Neural Networks for Predicting Drug-Target Interactions

  2018cites this paper
• High-throughput quantum-mechanics/molecular-mechanics (ONIOM) macromolecular crystallographic refinement with PHENIX/DivCon: the impact of mixed Hamiltonian methods on ligand and protein structure

  2018cites this paper
• Insight Analysis of Promiscuous Estrogen Receptor α-Ligand Binding by a Novel Machine Learning Scheme.

  2018cites this paper
• Construction of Fluorinated Benzoxathiin Skeleton by Successive Perfluorophenylthiolation/Cyclization of Activated α-Methylene Ketones by Perfluorophenyl Diethylaminosulfur Difluoride.

  2017cites this paper
• Synthesis of Sulfur Perfluorophenyl Compounds Using a Pentafluorobenzenesulfonyl Hypervalent Iodonium Ylide.

  2017cites this paper
• Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells

  2016cites this paper
• REGULATION OF CANCER METASTASIS BY PROTEIN KINASE D1: A GLOBAL REGULATORY CASCADE

  2016cites this paper
• Rationally Modified Estrogen Receptor Protein as a Bio-Recognition Element for the Detection of EDC Pollutants: Strategies and Opportunities

  2015cites this paper
• Etude de la férutinine et de ses analogues : hémisynthèse et activité anticancéreuse vis-à-vis des lignées cellulaires hormono-dépendantes

  2015cites this paper
• DOCK 6: Impact of new features and current docking performance

  2015cites this paper
• Discovery of Novel Selective ERα/ERβ Ligands by Multi-pharmacophore Modeling and Virtual Screening.

  2015cites this paper
• Ultrafast protein structure-based virtual screening with Panther

  2015cites this paper
• Docking-based classification models for exploratory toxicology studies on high-quality estrogenic experimental data.

  2015cites this paper
• Molecular design, synthesis and evaluation of 2,3-diarylquinoxalines as estrogen receptor ligands.

  2015cites this paper
• β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand.

  2014cites this paper
• Versatility or Promiscuity: The Estrogen Receptors, Control of Ligand Selectivity and an Update on Subtype Selective Ligands

  2014cites this paper
• Structure-Based Virtual Screening of Compound Library for Anti-Estrogen Breast Cancer Candidates

  2014cites this paper
• Copper‐Mediated One‐Pot Access to 2,3‐Dihydrobenzo[b][1,4]oxathiines from o,o′‐Dihydroxydisulfides

  2014cites this paper
• A Large-Scale Test of Free-Energy Simulation Estimates of Protein-Ligand Binding Affinities

  2014cites this paper
• Rational Modification of Estrogen Receptor by Combination of Computational and Experimental Analysis

  2014cites this paper
• Steroids - Basic Science

  2012cites this paper
• Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide.

  2012cites this paper
• Theoretical Studies of Anti-cancer Drug Tamoxifen and Estrogen Receptor Alpha

  2012cites this paper
• Theoretical Studies of Anti-cancer Drug Tamoxifen and Estrogen Receptor Alpha

  2012cites this paper
• Drug Design Approaches to Manipulate the Agonist-Antagonist Equilibrium in Steroid Receptors

  2012cites this paper
• Conformational Enantiomerization and Estrogen Receptor α Binding of Anti-Cancer Drug Tamoxifen and Its Derivatives

  2011cites this paper
• Role of cyclic tertiary amine bioactivation to reactive iminium species: structure toxicity relationship.

  2011cites this paper
• Gold-catalyzed intermolecular hydrophenoxylation of unactivated internal alkynes.

  2010cites this paper
• Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.

  2010cites this paper
• Dihydrobenzo[1,4]oxathiine: A multi-potent pharmacophoric heterocyclic nucleus.

  2010cites this paper
• Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.

  2010cites this paper
• Estrogen Receptors: Their Actions and Functional Roles in Health and Disease

  2010cites this paper
• Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases: Part 2: Use of non-steroidal ligands

  2009cites this paper
• Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.

  2009cites this paper
• Identification of xenoestrogens in food additives by an integrated in silico and in vitro approach.

  2009cites this paper
• Synthesis of β-functionalized ethyl polyfluoroaryl sulfides, sulfoxides, and sulfones underlain by pentafluorobenzoic acid

  2009cites this paper
• Recent advances in selective estrogen receptor modulators for breast cancer.

  2009cites this paper
• Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.

  2009cites this paper
• How computational methods try to disclose the estrogen receptor secrecy--modeling the flexibility.

  2009cites this paper
• Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus.

  2008cites this paper
• Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.

  2008cites this paper
• Prediction of binding affinity for estrogen receptorα modulators using statistical learning approaches

  2008cites this paper
• Beta-lactam type molecular scaffolds for antiproliferative activity: synthesis and cytotoxic effects in breast cancer cells.

  2008cites this paper
• β-Lactam type molecular scaffolds for antiproliferative activity: Synthesis and cytotoxic effects in breast cancer cells

  2008cites this paper
• Technique for Generating Three-Dimensional Alignments of Multiple Ligands from One-Dimensional Alignments

  2008cites this paper
• Synthesis and evaluation of estrogen agonism of diaryl 4,5-dihydroisoxazoles, 3-hydroxyketones, 3-methoxyketones, and 1,3-diketones: a compound set forming a 4D molecular library.

  2008cites this paper
• Subtype‐Selective Estrogens

  2008cites this paper
• 1,4-Dioxins, Oxathiins, Dithiins, and their Benzo Derivatives

  2008cites this paper
• Selective estrogen receptor modulator medicinal chemistry at Merck. A review.

  2008cites this paper
• Tamoxifen: catalyst for the change to targeted therapy.

  2008cites this paper
• Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.

  2007cites this paper
• Diverse, high-quality test set for the validation of protein-ligand docking performance.

  2007cites this paper
• Molecular aspects of phytoestrogen selective binding at estrogen receptors.

  2007cites this paper
• Target specific virtual screening: optimization of an estrogen receptor screening platform.

  2007cites this paper
• Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ERalpha.

  2007cites this paper
• Estrogen receptors: how do they signal and what are their targets.

  2007cites this paper
• Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells

  2007cites this paper
• Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics.

  2007cites this paper
• Bridged androstenediol analogs as ER-β selective SERMs

  2007cites this paper
• Bridged androstenediol analogs as ER-beta selective SERMs.

  2007cites this paper
• Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).

  2007cites this paper
• Structural features of diverse ligands influencing binding affinities to estrogen α and estrogen β receptors. Part II. Molecular descriptors calculated from conformation of the ligands in the complex resulting from previous docking study

  2007cites this paper
• Chapter 10 Novel Selective Estrogen Receptor Modulators (SERMs)

  2007cites this paper
• The 2.0 Å crystal structure of the ERα ligand‐binding domain complexed with lasofoxifene

  2007cites this paper
• Antagonist-induced, activation function-2-independent estrogen receptor α phosphorylation

  2006cites this paper
• Estrogen receptors: molecular interactions, virtual screening and future prospects.

  2006cites this paper
• Structure–function relationship of estrogen receptor α and β: Impact on human health

  2006cites this paper
• Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.

  2006cites this paper
• The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands.

  2006cites this paper
• Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists.

  2006cites this paper
• Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.

  2006cites this paper
• Androstenediol analogs as ER-beta-selective SERMs.

  2006cites this paper
• Structure-function relationship of estrogen receptor alpha and beta: impact on human health.

  2006cites this paper
• Lessons learnt from structural studies of the oestrogen receptor.

  2006cites this paper
• Estrogen receptor beta-subtype selective tetrahydrofluorenones: use of a fused pyrazole as a phenol bioisostere.

  2006cites this paper
• Androstenediol analogs as ER-β-selective SERMs

  2006cites this paper
• Estrogen receptor modulator review

  2006cites this paper
• Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.

  2005cites this paper
• Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.

  2005cites this paper
• In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinone type metabolites.

  2005cites this paper
• Reflections on the Discovery and Significance of Estrogen Receptor (cid:1)

  2005cites this paper
• Estrogen receptor ligands. 12. Synthesis of the major metabolites of an ERalpha-selective, dihydrobenzoxathiin antagonist for osteoporosis.

  2005cites this paper
• Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.

  2005cites this paper
• Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective.

  2005cites this paper